LIXT רווח למניה בשנים עשר החודשים האחרונים Lixte Biotechnology, Inc.

Lixte Biotechnology (LIXT) is targeting expansion by scaling its LB-100 platform to enhance chemotherapy. The fundamental TTM net income per share metric visualizes these ambitions, with this figure equaling -1.12. A current R&D plateau and a lack of sales are constraining financial growth, while drug delivery to medical centers relies on strict pharmaceutical transportation standards.

Lixte Biotechnology focuses on developing highly specialized protein phosphatase inhibitors for chemotherapy. A heavy reliance on a single molecule makes earnings per share a key indicator of financial stability. This metric divides total net income by the number of shares, eliminating the impact of issuance manipulations. This allows for an assessment of the investor's actual equity income. Analyzing the 12-month net income per share chart helps in rebalancing the portfolio in a timely manner.